Robertson Stephens Wealth Management’s CytomX Therapeutics CTMX Stock Holding History

Robertson Stephens Wealth Management’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$360K	Buy	+96,000	New	+$367K	0.01%	491

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Robertson Stephens Wealth Management's CTMX Position: Q2 2026 in Review

Robertson Stephens Wealth Management opened a new position in CytomX Therapeutics (CTMX) in Q2 2026: 96,000 shares worth $360K. The stake represents 0.01% of the portfolio and ranks #491 among its holdings.

178 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

Robertson Stephens Wealth Management held 96,000 shares of CytomX Therapeutics worth $360K as of Q2 2026.
CytomX Therapeutics was a new Robertson Stephens Wealth Management position in Q2 2026.
CytomX Therapeutics made up 0.01% of Robertson Stephens Wealth Management's portfolio in Q2 2026, its #491 holding.
178 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Robertson Stephens Wealth Management's 13F filing for Q2 2026, filed 29 Jul 2026.